Identification of a novel family of BRAF(V600E) inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• The BRAF oncoprotein is frequently mutated in cancers, particularly malignant melanoma, with the BRAF(V600E) mutation driving over 90% of these cases.
• Existing BRAF(V600E) inhibitors have limitations, necessitating the development of alternative therapeutic strategies.

Purpose of the Study:

• To identify novel inhibitors targeting the BRAF(V600E) oncoprotein.
• To characterize the mechanism of inhibition and explore structure-activity relationships for improved drug design.

Main Methods:

• High-throughput screening using an ELISA-based assay to identify BRAF(V600E) inhibitors.
• X-ray crystallography to determine the binding mode of inhibitors.
• Structure-based medicinal chemistry to synthesize and optimize naphthol analogues.
• In vitro kinase assays and cellular assays to assess inhibitory activity and signaling pathway modulation.

Main Results:

• Identification of a novel class of quinolol/naphthol compounds with preferential inhibition of BRAF(V600E) over wild-type BRAF and other kinases.
• Determination of the X-ray crystal structure revealing the inhibition mechanism.
• Development of naphthol analogues with in vitro IC(50) values in the 80-200 nM range.
• Demonstration of MAPK signaling inhibition in melanoma cells by the developed compounds.

Conclusions:

• Quinolol/naphthol compounds represent a promising new scaffold for developing selective BRAF(V600E) inhibitors.
• Structure-based drug design can yield potent and selective inhibitors for cancer therapy.
• Further optimization holds potential for improved efficacy and reduced liabilities in clinical applications.